Halozyme Therapeutics reported $132.61M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amarin USD 158.85M 5.22M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Baxter International USD 2.3B 41M Sep/2026
Cara Therapeutics USD 900K 0 Mar/2025
Cytokinetics USD 807K 427K Sep/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Halozyme Therapeutics USD 132.61M 4.52M Sep/2026
Intrexon USD 287K 68K Dec/2022
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
MannKind USD 48.47M 4.05M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Pfizer USD 10.02B 77M Sep/2026
Rigel Pharmaceuticals USD 13.3M 2.88M Sep/2025
United Therapeutics USD 201.9M 8.1M Sep/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025